Devita, Hellman, and Rosenberg's Cancer

LWBK1006-42 LWW-Govindan-Review December 12, 2011 20:38

526 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 42.4. Which conditioning regimen leads to improved disease-free survival in

chronic myeloid leukemia (CML)?

A. Cyclophosphamide 60 mg/kg/d IV×2 days plus busulfan 3.2 mg/kg/d

IV×4 days

B. 1200 cGy TBI and cyclophosphamide 60 mg/kg/d IV×2 days

C. Chemotherapy and radiation-based conditioning are equivalent

D. Fludarabine 30 mg/kg/d IV ×5 plus busulfan 3.2 mg/kg/d IV

×2 plus ATG 2.5 mg/kg/d IV× 4

Question 42.5. Which of the following drugs used in the conditioning regimens for stem

cell transplant (SCT) is the most common cause of acute cardiac toxicity?

A. Cytarabine

B. Mitoxantrone

C. Cyclophosphamide

D. Busulfan

Question 42.6. TBI-based conditioning is associated with an increased risk of all the

following, EXCEPT:

A. Cataracts

B. Growth retardation

C. Veno-occlusive disease (VOD)

D. Secondary malignancies

Question 42.7. The GVL effect after transplant is MOST pronounced in which of the

following malignancies?

A. Acute myelogenous leukemia (AML)

B. ALL

C. Chronic-phase CML

D. Accelerated-phase CML

Question 42.8. Which of the following increases the risk of relapse after transplant?

A. Human leukocyte antigen (HLA)-mismatched transplant

B. CD34 cell dose> 2 ×106 but< 5 ×106/kg recipient body weight

C. Acute and chronic GVHD

D. T-cell–depleted graft

Question 42.9. Each of the following measures is effective at reducing the indicated

regimen-related toxicities, EXCEPT:

A. Hydration, mesna (sodium 2-sulfanylethanesulfonate), and forced

diuresis during cyclophosphamide for prevention of hemorrhagic cys-

titis

B. Phenytoin before and during busulfan infusion for prevention of

seizures

C. Dexamethasone and ondansetron before conditioning for nausea pro-

phylaxis

D. Granulocyte colony-stimulating factor (G-CSF) growth factor sup-

port to decrease infection-related mortality